Monozyme
In the Dec 2025 quarter, revenue rose 42.3% year on year to ₹49.28 Cr and net profit was ₹1.74 Cr, against ₹1.06 Cr a year earlier (compared with Dec 2024). Promoters held 55.12% of Monozyme in Jan 2026, down 17.88 percentage points from Sep 2025.
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| ₹1,764.00 | 34.99 | 4,23,243 Cr | 5.06 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,667.50 | 87.74 | 2,56,642 Cr | 15.31 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,590.60 | 72.07 | 1,74,612 Cr | 9.50 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,194.10 | 108.40 | 1,18,550 Cr | 22.37 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,183.90 | 26.34 | 1,18,094 Cr | 4.36 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,338.70 | 34.67 | 1,11,739 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,365.70 | 32.72 | 1,10,329 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
Monozyme (this company) | — | — | — | — | — | — | — | 84 Cr | 3 Cr |
| Median 8 companies | ₹1,764.00 | 34.99 | 1,18,550 Cr | 5.06 | 0.61% | 13.79% | 17.94% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
4- Company has low interest coverage ratio.
- Company has a low return on equity of -24.5% over last 3 years.
- Company has high debtors of 50,127 days.
- Working capital days have increased from 15,794 days to 46,842 days
Growth Rate
change over 1 year
change over 1 year
Quarterly Results
| Particulars | Dec 2024 | Dec 2025 |
|---|---|---|
| Sales | 34.63 | 49.28 |
| Expenses | 25.13 | 37.94 |
| Operating Profit | 9.5 | 11.34 |
| OPM % | 27.43% | 23.01% |
| Other Income | 0.08 | 0.03 |
| Interest | 3.41 | 4.57 |
| Depreciation | 5.29 | 4.6 |
| PBT | 0.88 | 2.2 |
| Tax % | -20.45% | 21.36% |
| Net Profit | 1.06 | 1.74 |
| EPS (₹) | 0.43 | 0.71 |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 |
|---|---|---|---|
| Sales | 10.55 | 4.96 | 0.03 |
| Expenses | 9.63 | 5.62 | 1.95 |
| Operating Profit | 0.92 | -0.66 | -1.92 |
| OPM % | 8.72% | -13.31% | -6400% |
| Other Income | 0.05 | 0.06 | 2.22 |
| Interest | 0.38 | 0.49 | 0.37 |
| Depreciation | 0.08 | 0.13 | 0.1 |
| PBT | 0.51 | -1.22 | -0.17 |
| Tax % | 35.29% | 7.38% | 0% |
| Net Profit | 0.33 | -1.31 | -0.17 |
| Div. Payout % | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 |
|---|---|---|---|
| Equity Capital | 3.12 | 3.12 | 3.12 |
| Reserves | -0.23 | -1.54 | -1.71 |
| Borrowings | 5.38 | 4.93 | 2.72 |
| Other Liabilities | 2.96 | 1.49 | 0.72 |
| Total Liabilities | 11.23 | 8 | 4.85 |
| Fixed Assets | 0.71 | 0.59 | 0.4 |
| CWIP | 1.34 | 1.34 | 0 |
| Investments | 0 | 0 | 0 |
| Other Assets | 9.18 | 6.07 | 4.45 |
| Total Assets | 11.23 | 8 | 4.85 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 |
|---|---|---|---|
| Operating | -1.35 | — | — |
| Investing | -1.02 | — | — |
| Financing | 2.8 | — | — |
| Net Cash Flow | 0.43 | — | — |
| Free Cash Flow | -2.41 | — | — |
| CFO/OP | -127 | — | — |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 |
|---|---|---|---|
| Debtor Days | 190 | 330 | 50,127 |
| Inventory Days | 155 | 140 | 0 |
| Days Payable | 158 | 52.76 | — |
| Cash Conversion Cycle | 187 | 418 | 50,127 |
| Working Capital Days | 192 | 347 | 46,842 |
| ROCE % | — | -9.88% | -5.08% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Monozyme insights
38 extracted metrics + investor summaries across FY06–FY26.
Documents
Frequently Asked Questions about Monozyme
What does Monozyme India Ltd do?
Where is Monozyme India Ltd (522199) listed?
Which sector does Monozyme India Ltd belong to?
Company Information
Monozyme India Ltd is engaged in Healthcare/Hospitals business.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/522199.md for Monozyme India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.